In last trading session, Caribou Biosciences Inc (NASDAQ:CRBU) saw 1.64 million shares changing hands with its beta currently measuring 2.49. Company’s recent per share price level of $1.83 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $170.20M. That closing price of CRBU’s stock is at a discount of -63.93% from its 52-week high price of $3.00 and is indicating a premium of 63.93% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.49 million shares which gives us an average trading volume of 1.40 million if we extend that period to 3-months.
For Caribou Biosciences Inc (CRBU), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.42 in the current quarter.
Caribou Biosciences Inc (NASDAQ:CRBU) trade information
Caribou Biosciences Inc’s shares saw a change of -14.08% in year-to-date performance and have moved 5.17% in past 5-day. Caribou Biosciences Inc (NASDAQ:CRBU) showed a performance of 63.39% in past 30-days. Number of shares sold short was 10.95 million shares which calculate 9.39 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 39.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -63.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -63.93% for stock’s current value.
Caribou Biosciences Inc (CRBU) estimates and forecasts
This year revenue growth is estimated to fall -4.54% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.64M for the same. And 6 analysts are in estimates of company making revenue of 1.69M in the next quarter. Company posted 3.46M and 2.02M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -33.41% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 9.52% while estimates for its earnings growth in next 5 years are of 4.16%.
Caribou Biosciences Inc (NASDAQ:CRBU)’s Major holders
Insiders are in possession of 9.83% of company’s total shares while institution are holding 53.30 percent of that, with stock having share float percentage of 59.11%. Investors also watch the number of corporate investors in a company very closely, which is 53.30% institutions for Caribou Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CRBU for having 6.95 million shares of worth $11.39 million. And as of 2024-06-30, it was holding 7.6907 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.54 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.0306 of outstanding shares, having a total worth of $7.45 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.7 shares of worth $4.94 million or 2.91% of the total outstanding shares. The later fund manager was in possession of 2.1 shares on May 31, 2025 , making its stake of worth around $3.84 million in the company or a holder of 2.26% of company’s stock.
